HELP LINE:
844-775-2273
Customized support for patients with metastatic uveal melanoma (mUM) who have been prescribed KIMMTRAK® (tebentafusp-tebn)
Meet your team
We offer proactive services and support tailored to your specific needs.
Financial assistance
Our team is here to help make your treatment more affordable.
Enroll
Enrolling in KIMMTRAK CONNECT
should be quick and easy.

KIMMTRAK CONNECT® is a support program available at no cost for adult patients receiving KIMMTRAK infusion for the treatment of metastatic uveal melanoma (mUM). Sponsored by Immunocore, the program matches patients and caregivers with a dedicated nurse case manager who is US-based and provides customized support—from financial assistance to scheduling appointments to educational support.

Please see the KIMMTRAK Patient Information and Important Safety Information below including BOXED WARNING for Cytokine Release Syndrome (CRS).

Watch this video to learn more about what KIMMTRAK CONNECT has to offer.

Customized
support

Your dedicated nurse case manager will help guide you through the services and support we offer.

Care
coordination

Just tell us what you need, and we will try to help you manage your care. We may be able to assist you in locating affordable transportation to and from your treatment. We can also help coordinate infusion appointments once you and your physician choose a treatment location.

Financial
assistance

We identify the options that are right for you. Once we understand your needs, we will help set you up with financial assistance.

Let's get started.

We focus on making enrollment quick and easy.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).

Other ways to enroll

Call a dedicated
nurse case manager

We’re ready to help walk you through the enrollment process.

844-775-CARE (2273)

Available Monday-Friday, 9 AM-7 PM (EST)
Additionally, someone is available to help you 24/7.


Download a form

Fill out an enrollment form and send it to us.

Download
KIMMTRAK CONNECT Co-pay Support Program Terms and Conditions

To receive benefits under the KIMMTRAK CONNECT Co-pay Support Program (“Program”), the patient must enroll into the Program and attest the patient meets the eligibility criteria and agrees to and will comply with the terms and conditions described below:

  • Patient must be prescribed KIMMTRAK for an FDA-approved indication, be 18 years of age or older, and be a resident of the United States or Puerto Rico. Patient must have commercial health insurance, but insurance does not cover the full cost of KIMMTRAK.
  • Program expires on December 31, 2024, and is subject to an annual cap of $7,500. Patient is responsible for any applicable taxes, fees, or amounts exceeding the annual cap.
  • Program is not valid for patients without commercial health insurance or whose prescription claims for KIMMTRAK are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, Department of Defense (DoD), Department of Veterans Affairs (VA), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance Plan, or any state patient or pharmaceutical assistance program.
  • Subject to changes in state law, the Program may become invalid for Massachusetts residents prior to its expiration date.
  • Program benefits are limited to the co-pay or coinsurance costs for doses of KIMMTRAK only. The Program will not cover, and shall not be applied toward, the cost of any dosing procedure, any other healthcare provider service or supply charges, any other treatment costs such as office visits or administration charges, or any costs associated with a hospital stay even if such costs are associated with the administration of KIMMTRAK.
  • Patient or healthcare provider must submit an Explanation of Benefits (EOB) from the patient’s insurance within 180 days from the date of the EOB. The EOB must include the name of the patient receiving the co-pay/coinsurance benefit, name of the insurer and plan, and that KIMMTRAK was the product administered.
  • Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount received from the Program.
  • Acceptance of this offer confirms that this offer is consistent with the patient’s insurance and that the patient will report the value of the Program benefit received as may be required by the patient’s insurance provider.
  • This offer is not valid with any other financial support program, patient assistance program (PAP), discount, discount card, cash discount card, free trial, coupon, or incentive involving KIMMTRAK.
  • Participation in the Program requires a valid patient HIPAA authorization.
  • Only valid in the United States and Puerto Rico; this offer is void where restricted or prohibited by law.
  • The Program benefits are nontransferable.
  • This offer is not conditioned on any past, present, or future purchase, including additional doses of KIMMTRAK.
  • The Program is not insurance.
  • Immunocore reserves the right to terminate, rescind, revoke, or amend this offer at any time without notice.
Indication
 
Important Safety Information Including Boxed Warning
KIMMTRAK is a prescription medicine used to treat HLA-A*02:01-positive adults with uveal melanoma that cannot be removed by surgery or has spread.
KIMMTRAK can cause serious side effects that can be severe or life threatening and usually with the first three infusions, including:
  • Cytokine Release Syndrome (CRS). Symptoms of CRS may include:

Indication and Important Safety Information Including Boxed Warning

Usage

KIMMTRAK is a prescription medicine used to treat HLA-A*02:01-positive adults with uveal melanoma that cannot be removed by surgery or has spread.

Important Safety Information

What is the most important information I should know about KIMMTRAK?

KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including:

  • Cytokine Release Syndrome (CRS). Symptoms of CRS may include:
    • fever
    • tiredness or weakness
    • vomiting
    • chills
    • nausea
    • low blood pressure
    • dizziness and light-headedness
    • headache
    • wheezing and trouble breathing
    • rash

Tell your healthcare provider right away if you get any of these symptoms. Your healthcare provider will check for these problems during treatment with KIMMTRAK. Your healthcare provider may temporarily stop or completely stop your treatment with KIMMTRAK if you have severe side effects.

See "KIMMTRAK can cause other serious side effects" for more information.

Before receiving KIMMTRAK, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. KIMMTRAK may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with KIMMTRAK.For females who are able to become pregnant:
    • Your healthcare provider should do a pregnancy test before you start treatment with KIMMTRAK.
    • Use an effective form of birth control during treatment with KIMMTRAK and for at least 1 week after the last dose of KIMMTRAK.
  • are breastfeeding or plan to breastfeed. It is not known if KIMMTRAK passes into your breast milk. Do not breastfeed during the treatment with KIMMTRAK and for at least 1 week after the last dose of KIMMTRAK.

Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

KIMMTRAK can cause other serious side effects, including:
  • Skin reactions. KIMMTRAK may cause skin reactions that require treatment. Tell your healthcare provider if you get symptoms of skin reactions—such as rash, itching, or skin swelling—that are severe and do not go away.
  • Abnormal liver blood tests. Your healthcare provider will do blood tests to check your liver before you start KIMMTRAK and during treatment with KIMMTRAK. Tell your healthcare provider if you get symptoms of liver problems such as right-sided abdominal pain or yellowing of the skin or eyes.
The most common side effects of KIMMTRAK include:
  • cytokine release syndrome (CRS)
  • rash
  • fever
  • itching
  • tiredness
  • nausea
  • chills
  • stomach pain
  • swelling
  • low blood pressure (symptoms may
    include dizziness or light-headedness)
  • dry skin
  • headache
  • vomiting
  • abnormal liver blood tests

These are not all the side effects possible with KIMMTRAK.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).

Please read the accompanying Patient Information Leaflet before you receive KIMMTRAK and discuss any questions you have with your healthcare provider.

Please see KIMMTRAK Patient Information.